@FierceBiotech: Genmab's lymphoma project flops in Phase III with Novartis holding the bag. Article | Follow @FierceBiotech
@JohnCFierce: Any journos who would like to attend our #JPM16 breakfast event on Big Data? Drop me a line @ [email protected]. More info | Follow @JohnCFierce
@DamianFierce: Has anyone asked the presumptive FDA chief whether jet fuel can melt steel? More | Follow @DamianFierce
> BioMarin ($BMRN) is in the midst of a make-or-break meeting with FDA advisers over its in-development treatment for Duchenne muscular dystrophy. The Street's Adam Feuerstein is live-blogging the daylong discussion. More
> Bill Ackman, long a vocal supporter of the embattled Valeant Pharmaceuticals ($VRX), has acquired an even greater stake in the company. More
> Array BioPharma's ($ARRY) chief financial officer is stepping down after four months on the job. News
Medical Device News
@FierceMedDev: Startup gets $36.5M to conduct U.S. pivotal trial for novel endoscopic weight loss device. Article | Follow @FierceMedDev
@VarunSaxena2: ICYMI: Physicians call for novel abuse-deterrent opioid agonist/antagonist formulations in survey. FierceDrugDelivery story | Follow @VarunSaxena2
@EmilyWFierce: Dell teams up with Zebra Medical Vision for data analytics initiative. Report | Follow @EmilyWFierce
> Dell teams up with Zebra Medical Vision for data analytics initiative. Story
> Cigna launches genetic counseling program for hereditary cancers. Article
Pharma News
@FiercePharma: Japan's Takeda gets early U.S. FDA nod for ixazomib. More from FiercePharmaAsia | Follow @FiercePharma
@EricPFierce: ICYMI: Catalent halts production, calls authorities into French plant where tampering is suspected. Article | Follow @EricPFierce
@CarlyHFierce: With veteran job-choppers Pfizer and Allergan joining hands, how many layoffs are in the cards? More | Follow @CarlyHFierce
> Trump, Clinton lash out at Pfizer over Allergan deal agreement. More
> Forget Pfizer and Allergan, Teva is the pharma getting the most market love these days. Report
> JAMA: Gilead, AbbVie hep C meds cost-effective even in early stages of liver disease. Article
Drug Delivery News
> Depomed acquires pain candidate for $25M as it fends off Horizon's hostile takeover. Item
> AstraZeneca begins dosing in trial of its Bind-partnered cancer candidate. More
> J&J leads $24M financing into maker of OTC 'liquid shots' for common ailments. Report
> Pills loaded with mucoadhesive patches could make oral insulin a reality. Story
> Adapt Pharma earns FDA approval of first intranasal spray for emergency opioid overdose. Article
Pharma Manufacturing News
> Novo Nordisk says all its manufacturing plants will run on renewable electricity by 2020. News
> Abzena to raise $30M to buy another U.S. contract drug developer. Report
> Some production resumes at Strides Shasun facility following fire that killed one. More
> Synerlab buys contract manufacturing developer Alcala Farma for undisclosed price. Story
> South Africa's Ascendis picks up manufacturing facility in $24.6M deal for Akacia. Article
Pharma Asia News
> India's Biocon chief says R&D tax breaks essential for investment. Story
> China's ZAI Lab in oncology license deal for HM61713 with South Korea's Hanmi. More
> India's gliptin market ready for a shakeup by Zydus at 11 U.S. cents a pill. Report
> Japan's Takeda gets early U.S. FDA nod for ixazomib. Item
> India-EU trade talks back on next year, GVK issue sidelined. Article